Heather H. Cheng, MD, PhD, an associate professor of medical oncology at the University of Washington School of Medicine, and director of the Seattle Cancer Care Alliance Prostate Cancer Genetics Clinic, discusses the role of genetic testing in prostate cancer as it continues to evolve in this space. This year, the 2019 National Comprehensive Cancer Network (NCCN) guidelines focused more on genetic testing in select patients with prostate cancer.

Genetic testing, genetic counseling, and issues surround genetics are taking on a larger role in the realm of prostate cancer, Cheng says. It is making an impact in primary care, urology, internal medicine, and oncology. Genetic testing provides new opportunities for patients with prostate cancer.

Cheng encourages physicians and patients to speak with genetic counselors, who play a critical role in the diagnosis and treatment or prostate cancer. There is a lot of demand now for how genetic testing is used in this patient population due to the constraints of the existing system. Overall as the medical field, Cheng says that access to testing in these patients needs to be increased to ensure patients are receiving quality care.

For more resources and information regarding anticancer targeted therapies in prostate cancer: [ Ссылка ]

свернуть